Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04644250
Other study ID # GLYY-EC-NAD-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 1, 2020
Est. completion date March 1, 2024

Study information

Verified date November 2020
Source The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact Wei Ren
Phone 13915981834
Email renwei@njglyy.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Radical resection is thought to be the mainstay of esophageal cancer treatment. Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal squamous cell cancer (ESCC). However, only 20% to 40% of patients can achieve pathologic complete response (pCR) after neoadjuvant CRT with favorable prognosis and about 10% of patients have disease progression after chemoradiotherapy. How to improve the the efficacy of neoadjuvant therapy is an important clinical problem to be solved. Immunotherapy targeting the programmed cell death receptor-1(PD-1) /programmed cell death-Ligand 1(PD-L1) checkpoints has demonstrated promising activity in ESCC. In Keynote181 study, for patients with metastatic esophageal squamous cell carcinoma, regardless of PD-L1 expression, pembrolizumab significantly improved overall survival compared with chemotherapy. However, the efficacy and safety of immunotherapy therapy in surgery-based multidisciplinary treatment of local advanced esophageal cancer still need a lot of clinical studies to further confirm. This study aims to investigate the safety and efficacy of Toripalimab combined with radiotherapy and chemotherapy in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma


Description:

This study was designed as an open-lable, single-arm, single-center,exploratory clinical study. Toripalimab combination of chemoradiotherapy as neoadjuvant therapy. Participants will receive carboplatin (AUC=2) and paclitaxel liposome (50mg/m²) on day 3,10,17,24,31. And radiotherapy Intensity-modulated radiation therapy(IMRT)will start from day 1 to 31 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy. Participants will also receive Toripalimab (240mg) on days 3, 24and 45. After the neoadjuvant treatment is over, the short-term efficacy evaluation will be performed first, and then a radical resection will be scheduled on Day 59 to 73. This study include 2 phases: 14 cases were enrolled in the first stage and 18 cases were enrolled in the second stage.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date March 1, 2024
Est. primary completion date March 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Aged 18 to 70 years old of either gender 2. A histopathological diagnosis of resectable thoracic esophageal squamous cell carcinoma(The midpoint of the upper and lower margins of the primary tumor is =25cm from the incisor) 3. There is no distant metastasis and the esophageal tumor can be resected or potentially resectable after the expert consultation of thoracic surgery. The clinical stage is cT3-4aN0-2M0, patients with stage ?, ?, and IVA (AJCC 8th edition cTNM staging); 4. ECOG PS score of 0-1; 5. Patients who are anti-tumor treatment-naive; 6. Estimated life expectancy >6 months 7. Baseline the function of important organs meets the following requirements: a. white blood cell count (WBC) = 3×109/L, absolute neutrophil count (ANC) = 1.5×109/L,;Baseline organ function meets: ?WBC=3×109/L, ANC=1.5×109/L, PLT=100×109/L, Hb=90g/L; ?Liver function: TBIL=2ULN, Aspartate aminotransferase(AST) =2.5ULN, ALT=2.5ULN ?renal function: cCr=60 ml/min, Cr=1.5 ULN; ?heart function: no heart disease or coronary heart disease, the patient's heart function is 1-2 grade; 8. The blood pressure of hypertensive patients should be controlled within the normal range with antihypertensive drugs; 9. The fasting blood-glucose of diabetic patients should be controlled at =8mmol/L through hypoglycemic drugs; 10. No other serious diseases that conflict with this plan (such as autoimmune diseases, immunodeficiency, organ transplantation, or other diseases that require continuous hormone therapy); 11. No history of other malignant tumors; 12. The patient agrees to participate in this clinical study and signs the "Informed Consent". Ability to understand the study and sign informed consent. Exclusion Criteria: 1. Patients who have been treated previously with anti-tumor therapy (including chemotherapy, radiotherapy, surgery, immunotherapy, etc.); 2. Patients with other malignant tumors (non-malignant black skin tumors, cervical cancer in situ, except for cured prostate cancer); 3. Patients who have been or expected to have a significant risk of esophageal perforation, fistula, and major bleeding; 4. Patients who have active autoimmune diseases or patients who are undergoing treatment of autoimmune diseases (Prior therapy with immunosuppressant, the dose of immunosuppressant used =10mg/day, oral prednisone for more than 2 weeks);. 5. Uncontrolled clinically significant cardiovascular and cerebrovascular diseases , including but not limited to severe acute myocardial infarction, unstable or severe angina pectoris, coronary artery bypass surgery, congestive heart failure, ventricular arrhythmia requiring medical intervention within 6 months before enrollment ?Left ventricular ejection fraction <50%, or other patients who are not expected to tolerate chemotherapy and radiotherapy;Cardiac clinical symptoms or diseases that are not well controlled, such as: a. Heart Failure(New York Heart Association)> Class ?, b. unstable angina, c. myocardial infarction within 1 year; d. Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention. 6. Patients who were severe allergic constitution;; 7. Patients who were pregnant or lactating women; 8. Patients who have severe mental disorders; 9. Patients who have peripheral nerve disease with common terminology criteria (CTC)grade =3; 10. Abnormal blood coagulation function including PT>16s, activated partial thromboplastin time(APTT)>53s, Thrombin time(TT)>21s, Fib<1.5g/L, bleeding tendency or receiving thrombolytic or anticoagulant therapy; 11. Patients who hsve severe pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, severely impaired lung function, etc past or present., or active tuberculosis within 1 year; 12. Patients who have active hepatitis B or C; 13. Patients who did not meet the enrollment conditions xia researchers evaluated.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Toripalimab
Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45,3 cycles in total.
Paclitaxel liposome/Carboplatin
Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31, 5cycles in total.
Radiation:
Intensity-modulated radiotherapy
A total of 41.4 Gy, 23 fractions of 1.8 Gy on Day 1 to 31.

Locations

Country Name City State
China Nanjing Drum Tower Hospital Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Wei Ren

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathologic complete response rate Pathologic complete response was defined as pT0N0M0(clinical stage). The rate of pathologic complete response rate after neoadjuvant chemoradiotherapy. Three working days after surgery
Secondary Incidence of Treatment-related Adverse Events as Assessed by CTCAE v4.0 The neoadjuvant treatment-related adverse events From the enrollment to the date of surgery
Secondary 2-year overall survival The 2-year overall survival of the whole group From date of randomization until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 24 months
Secondary 2-year disease-free survival The 2-year disease-free survival of the whole group From date of surgery until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.
Secondary Major Pathological Response (MPR) rate MPR is defined as 10% or fewer viable cancer cells in the hematoxylin and eosin (H&E)-stained slides from the resected tumor following neoadjuvant treatment. From date of surgery to 14 days later
Secondary Objective Response Rate (ORR) Objective response rate is defined as the rate of patients with at least a 30% decrease in the sum of the longest diameter of target lesions, which include complete response (CR) or partial response (PR). At the end of Cycle 2 (each cycle is 21 days)
Secondary R0 resection rate The R0 resection rate of esophagectomy Three working days after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06056336 - Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma Phase 2
Suspended NCT04084158 - A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05561699 - Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer N/A
Active, not recruiting NCT04543617 - A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy Phase 3
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Completed NCT05557955 - Identification of Breath Biomarkers in Esophageal Cancer
Recruiting NCT04045496 - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Not yet recruiting NCT03766178 - Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT02913066 - S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT02399306 - Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma Phase 3
Completed NCT01605305 - Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer Phase 2
Not yet recruiting NCT05552651 - Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05520619 - Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) Phase 2
Terminated NCT03251417 - Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05990231 - Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy Phase 2
Completed NCT02916511 - Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma Phase 2
Terminated NCT04032704 - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Phase 2
Active, not recruiting NCT04063683 - Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC). Phase 2